Hyderabad based Dr Reddy’s Laboratories limited has announced its third quarter results ending 31st December 2014. Net profit for the quarter ending 31st December 2014 is at Rs 574.5 crore (USD 91 million), 15% of total revenue. A year ago company’s net profit was at Rs 618.4 crore, 17.5% of total revenue. Net profit for the quarter October-December FY 2015 has declined by 7% Year-on-Year.
During Q3 FY 2015, revenue for Dr Reddy’s Laboratories grew 9% to Rs 3843 crores as against Rs 3533 crores a year ago.
Revenues from the Global Generics segment are at Rs 31.69 billion, Year-on-Year growth of 8%. Revenue from North America is at Rs 16.82 billion, shown 4% year-on-year growth.
Revenue from Russia has declined by 10% year-on-year to Rs 4 billion. Revenue from India is at Rs 4.3 billion, shown 11% growth year-on-year.
During the quarter Dr Reddy’s launched 13 new generic products, filed 18 new product registrations and 14 DMFs globally.
Dr Reddy’s laboratories completed the acquisition of Habitrol franchise (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc. and began marketing the product in the U.S. Total consideration paid was USD 80 million.
Gross Profit which is derived after taking out cost of revenues from revenues is at Rs 2235 crores as against Rs 2139 crores. Dr Reddy’s Loboratories’s gross Profit Margin is at 58.2% in Q3 FY2015 versus 60.5% as in Q3 FY 14.
Research & Development (R&D) expenses is at Rs 431 Crore, 11.2% to revenues versus Rs 298 Crores as in Q3 FY14, 8.4% to revenues. R&D expenses has gone up by 45% Year-on-year. Selling, general & administrative expenses is at Rs 111 Crore, 29.0% to revenues.
Financial results of Dr Reddy’s Laboratories Limited – Rupees in millions
||Q3 FY2015 (Quarter ending 31st December 2014)
||Q3 FY2014 (Quarter ending 31st December 2013)
|Results from operating activities